Clario eCOA


CLARIO.


Helping sponsors capture the right data to prove drug efficacy

We partner with sponsors and CROs to ensure their trials are measuring the endpoints they need to prove drug efficacy.

eCOA solutions

Our eCOA solutions make participant data collection simple and fast and help bring drugs to market, faster.





Poor endpoint design or strategy can contribute to trial delays or even failure.

Connected devices

Connected devices make taking part in clinical studies straightforward. Clario's devices are pre-validated for use in clinical trials and integrated with the eCOA device to capture ECG, spirometry, blood glucose levels, activity levels, movement endpoints and many more.







Glucometer



iSpiro[®]



Actigraph Watch



Opal® Precision Motion Monitoring

Leading endpoint technology platform for pharma R&D

Data sets, technology and domain expertise deeply embedded in customer workflows

Sicol Imaginal Domain expertise 27,000 clinical trials supported 200+ therapeutic and endpoint experts • Involvement in 60% of all FDA approvals >250 regulatory >12K respiratory between 2019 and 2022 trials >600K participants >50K sites supported >90% new respiratory >30 years working Data science with regulators approvals Leading endpoint data solutions spanning CLARIO. medical imaging, eCOA, cardiac safety and respiratory efficacy and safety Generation of the richest clinical evidence >13K cardiac safety ~4K studies supported trials >600 QT endpoint >260K sites supported studies Technology solutions >580 new drug >2.5M participants supported approvals Broadest endpoint technology and service platform Backed by validated clinical trial management software, connected devices and artificial intelligence

- **01** Scientific expertise
- **O2** Evidence generation
- O3 Accelerated timelines
- **04** Improved workflows
- 05 Enhanced safety
- 06 Global regulatory expertise



